Woodline Partners’s Fractyl Health GUTS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.42M Sell
1,783,592
-458,087
-20% -$326K ﹤0.01% 875
2026
Q1
$1.03M Sell
2,241,679
-3,265,092
-59% -$3.01M ﹤0.01% 884
2025
Q4
$12.1M Buy
5,506,771
+237
+0% +$381 0.05% 414
2025
Q3
$8.76M Buy
5,506,534
+4,908,693
+821% +$6.37M 0.04% 459
2025
Q2
$969K Buy
597,841
+80,920
+16% +$131K 0.01% 807
2025
Q1
$615K Buy
516,921
+165,786
+47% +$265K ﹤0.01% 814
2024
Q4
$723K Sell
351,135
-68,840
-16% -$160K ﹤0.01% 798
2024
Q3
$1.06M Buy
419,975
+160,427
+62% +$523K 0.01% 507
2024
Q2
$1.11M Buy
259,548
+48,585
+23% +$313K 0.01% 457
2024
Q1
$1.56M Buy
+210,963
New +$1.78M 0.01% 442

Other funds holding GUTS

Woodline Partners's GUTS Position: Q2 2026 in Review

Woodline Partners reduced its Fractyl Health (GUTS) stake by 20% in Q2 2026, selling an estimated $326K and leaving 1,783,592 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #875.

Woodline Partners first reported a position in GUTS in Q1 2024 and has held it in 10 quarters since. The position peaked at $12.1M in Q4 2025. 77 funds tracked by Wall St. Rank hold GUTS as of Q2 2026.

  • Woodline Partners held 1,783,592 shares of Fractyl Health worth $1.42M as of Q2 2026.
  • Woodline Partners sold 458,087 Fractyl Health shares in Q2 2026, an estimated $326K.
  • Fractyl Health made up ﹤0.01% of Woodline Partners's portfolio in Q2 2026, its #875 holding.
  • Woodline Partners first reported a position in Fractyl Health in Q1 2024 and has held it in 10 quarters since.
  • Woodline Partners's Fractyl Health position peaked at $12.1M in Q4 2025.
  • 77 funds tracked by Wall St. Rank held Fractyl Health as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.